Table 1.
Interventions and Characteristics of Individual Studies
| Study | Study Design | Mean Age, y | Mean Follow‐Up Period | Antihypertensive Agent | Sample Size | Mean Follow‐Up, y | Mean Baseline BP, mm Hg | Mean Change of BP, mm Hg | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ACE Inhibitor | CCB | Diuretic | BB | ACE Inhibitor | CCB | Diuretic | BB | |||||||
| LIFE Study (2004) | Randomized clinical trial | 65 | 4.8 y | Losartan/atenolol | 270/263 | 4.8 | 172/97.9 | – | – | 171.8/97.7 | −30.3/17.3 | – | – | −29.1/−17.2 |
| ALLHAT study (2005) | Randomized clinical trial | 66 | 4 y | Lisinopril/amlodipine/chlorthalidone | 3210/5369/3213 | 4 | 146.2/84.9 | 146.1/84.7 | 146.3/84.9 | – | −6.8/−5.6 | −8.8/−6.6 | −10.5/−6.6 | – |
| AASK trial (2006) | Randomized clinical trial | 55 | 4.1 y | Ramipril/amlodipine/metoprolol | 436/217/441 | 4.1 | 151/96 | 150/96 | – | 150/95 | −16/−14 | −17/−15 | – | −15/−14 |
| Bangalore et al. (2015) | Propensity match cohort | 50 | 6 mo | ACE/CCB/diuretic/BB | Total sample 25,564 | 6 | 144/83 | 153/87 | 148/85 | 138/80 | – | – | – | – |
Abbreviations: AASK, African American Study of Kidney Disease and Hypertension trial; ACE, angiotensin‐converting enzyme; ALLHAT, Antihypertensive and Lipid‐Lowering Treatment to Prevent Heart Attack Trial; BB, β‐blocker; BP, blood pressure; CCB, calcium channel blocker; LIFE, Losartan Intervention For Endpoint Reduction trial.